Laurus Labs Limited
NSE: LAURUSLABS · Pharmaceuticals · sector
₹2,058.90NSE close 2026-10-26
Key numbers
Market cap₹1,11,232 cr
Price₹2,058.90
52w high / low₹2,089 / ₹902
P/E101.6xSector median 27.9x
P/B21.0xSector median 2.9x
Book value₹98.1
Dividend yield0.08%Sector median 0.48%
ROE22.4%Sector median 11.7%
ROCE20.8%Sector median 12.3%
OPM28.0%Sector median 14.0%
Debt / equity0.45xSector median 0.16x
EV/EBITDA55.8xSector median 18.6x
Interest cover9.9x
Current ratio1.33x
Sales growth 3y+4.1%Sector median +9.6%
Profit growth 3y+4.0%Sector median +13.3%
PEG26.15x
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹114 cr vs borrowings ₹2,397 cr (FY26): borrowings are higher by ₹2,284 cr.
- Operating profit covered interest 9.9x in the last 12 months.
- 2.19% of the promoters' shares are pledged (0.6% of all shares).
- Operating cash flow was below net profit in 0 of the last 5 years.
- Revenue was higher than a year earlier in 4 of the last 4 quarters.
- Other income was 5% of net profit in the last 12 months.
- Dividend paid in 5 of the last 5 financial years.
- Price ₹2,058.90 on 2026-10-26: -1.4% from the 52-week high, +128.2% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹2,060.10 · low ₹439.25
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,224 | 1,415 | 1,720 | 1,570 | 1,653 | 1,778 | 1,812 | 2,026 |
| EBITDA | 178 | 285 | 421 | 382 | 403 | 480 | 512 | 638 |
| OPM % | 14.6% | 20.2% | 24.4% | 24.3% | 24.4% | 27.0% | 28.3% | 31.5% |
| Other income | 5 | 9 | 59 | 10 | 27 | 6 | 12 | 9 |
| Net profit | 20 | 92 | 234 | 163 | 195 | 252 | 279 | 368 |
| EPS (₹) | 0.37 | 1.71 | 4.34 | 3.02 | 3.61 | 4.67 | 5.17 | 6.81 |
| Revenue YoY | +35.1% | +25.7% | +5.3% | +29.1% | ||||
| Profit YoY | +882.7% | +172.7% | +19.5% | +125.5% |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 4,936 | 6,041 | 5,041 | 5,554 | 6,813 | 7,270 |
| EBITDA | 1,422 | 1,592 | 778 | 1,055 | 1,778 | 2,034 |
| Net profit | 828 | 790 | 161 | 358 | 889 | 1,093 |
| EPS (₹) | 15.42 | 14.69 | 2.98 | 6.65 | 16.47 | 20.26 |
| Revenue growth | +22.4% | -16.6% | +10.2% | +22.7% | +22.6% | |
| Profit growth | -4.5% | -79.7% | +123.2% | +148.0% | +114.9% | |
| Dividend / share (₹) | 1.60 | 2.00 | 1.60 | 0.80 | 1.60 |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | +4.1% | +7.2% | +22.6% |
| Net profit | +4.0% | -2.0% | +114.9% |
| EPS | +3.9% | -2.1% | – |
| Share price | – | +108.0% (2y) | +117.8% |
Balance sheet
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Shareholders' equity | – | 4,038 | 4,111 | 4,473 | 5,300 |
| Borrowings | – | 1,972 | 2,507 | 2,693 | 2,397 |
| Cash & equivalents | – | 48 | 142 | 144 | 114 |
| Total assets | – | 7,660 | 8,387 | 9,336 | 10,511 |
| Fixed assets | – | 3,016 | 3,446 | 3,668 | 3,873 |
| Capital work in progress | – | 551 | 423 | 458 | 773 |
| Investments | – | 50 | 124 | 233 | 309 |
| Receivables | – | 1,580 | 1,663 | 2,007 | 2,155 |
| Inventory | – | 1,685 | 1,845 | 1,937 | 2,342 |
| Payables | – | 711 | 1,051 | 958 | 1,252 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash from operations | 911 | 994 | 666 | 602 | 1,624 |
| Cash from investing | -914 | -996 | -822 | -682 | -1,089 |
| Cash from financing | 30 | -27 | 250 | 39 | -525 |
| Capex | 877 | 990 | 678 | 641 | 1,070 |
| Free cash flow | 34 | 4 | -13 | -39 | 554 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ROE % | – | 19.6% | 3.9% | 8.0% | 16.8% |
| ROCE % | – | 21.2% | 6.3% | 9.8% | 17.6% |
| Debtor days | – | 95 | 120 | 132 | 115 |
| Inventory days | – | 222 | 277 | 285 | 317 |
| Payable days | – | 93 | 158 | 141 | 170 |
| Cash conversion cycle (days) | – | 224 | 239 | 276 | 262 |
| Working capital days | – | 62 | 52 | 52 | 64 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 27.47% |
| FIIs | 30.84% |
| DIIs | 11.86% |
| of which Mutual funds | 8.26% |
| of which Insurance | 2.35% |
| Public (non-institutions) | 29.83% |
| Quarter | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters % | 27.62% | 27.62% | 27.59% | 27.59% | 27.49% | 27.49% | 27.47% | 27.47% |
| Promoter group | % |
|---|---|
| M/s. NSN Holdings (Represented by its Managing Partner, Dr. Satyanarayana Chava) | 22.97% |
| Chunduru Venkata Lakshmana RAO | 2.65% |
| M/s. Leven Holdings (Represented by its Managing Partner, Mr. Venkata Ravi Kumar Vantaram) | 1.15% |
| Satyanarayana Chava | 0.29% |
| Venkata Ravi Kumar Vantaram | 0.19% |
| Krishnaveni Vasireddi | 0.04% |
| Hymavathi Vantaram | 0.04% |
| Rama Suryadevara | 0.03% |
| Narasimha RAO Suryadevara | 0.03% |
| Chava Narasimha RAO | 0.02% |
| Sekhar Babu Chunduru | 0.02% |
| Nagamani Thokala | 0.02% |
| Chandrakanth Chereddi | 0.01% |
| Satya TEJ Chava | 0.01% |
| Rishi TEJ Chava | 0.01% |
| Public holders above 1% | % |
|---|---|
| Mirae Asset Nifty India Manufacturing ETF | 4.02% |
| NEW World Fund INC | 3.53% |
| Anukar Projects Private Limited | 3.24% |
| Smallcap World Fund, INC | 2.26% |
| Barclays Wealth Trustees India Private Limited | 1.55% |
| Akash Bhanshali | 1.32% |
| SBI Life Insurance Co. Ltd | 1.07% |
| Vanguard Total International Stock Index Fund | 1.00% |
3,11,892 shareholders. Pledged: 2.19% of promoter shares.
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| LUPIN | ₹89,616 cr | 16.2x | 4.0x | 27.9% | 27.9% | 30.0% | +18.9% | 0.61% |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2026-05-08 | Dividend | Interim Dividend - Rs 1.20 Per Share |
| 2025-10-31 | Dividend | Interim Dividend - Re 0.80 Per Sh |
| 2025-05-09 | Dividend | Interim Dividend - Rs 0.80 Per Share |
| 2024-11-06 | Dividend | Interim Dividend - Rs 0.40 Per Share |
| 2024-07-04 | Other | Annual General Meeting |
| 2024-05-08 | Dividend | Interim Dividend - Re 0.40 Per Share |
| 2023-11-02 | Dividend | Interim Dividend - Re 0.40 Per Share |
| 2023-07-07 | Other | Annual General Meeting |
| 2023-05-10 | Dividend | Interim Dividend - Rs 1.20 Per Share |
| 2022-11-03 | Dividend | Interim Dividend - Rs 0.80 Per Share |
| 2022-06-22 | Other | Annual General Meeting |
| 2022-05-10 | Dividend | Interim Dividend - Rs 1.20 Per Share |
| 2021-11-17 | Dividend | Interim Dividend - Rs 0.80 Per Share |
| 2021-07-07 | Other | Annual General Meeting |
| 2021-05-11 | Dividend | Interim Dividend - Re 0.80 Per Share |
| 2021-02-08 | Dividend | Interim Dividend - Rs 0.40 Per Share |
| 2020-11-10 | Dividend | Interim Dividend - Rs 0.80 Per Share |
| 2020-09-29 | Split | Face Value Split (Sub-Division) - From Rs 10/- Per Share To Rs 2/- Per Share |
| 2020-07-01 | Dividend | Annual General Meeting/Dividend - Re 1 Per Share |
| 2020-03-23 | Dividend | Interim Dividend - Rs 1.50 Per Share |
Documents
- Annual report FY26
- Annual report FY25
- Annual report FY24
- Annual report FY23
- Annual report FY22
- Announcements NSE filings
- BRSR FY26
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
- Pharmaceuticals & Bio product: Development, manufacturing & services related to chemicals & chemical products, pharmaceuticals, medicinal chemical, bio & botanical products
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | LAURUSLABS |
| BSE code | 540222 |
| ISIN | INE947Q01028 |
| Face value | ₹2.0 |
| Incorporated | 2005-09-19 |
| Website | www.lauruslabs.com |
| Plants (India / abroad) | 8 / 0 |
From the company's filings (BRSR FY26).
Data built 2026-10-22 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.